# A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

> **NCT03420768** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 61 (actual)

## Conditions studied

- Hepatic Cirrhosis
- Liver Fibrosis

## Interventions

- **DRUG:** BMS-986263
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03420768
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-14
- **Primary completion:** 2018-12-10
- **Final completion:** 2019-05-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03420768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03420768, "A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03420768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*